SARS-CoV-2 is a betacoronavirus that belongs to the family Coronaviridae and the order Nidovirales ( 1 ). During December 2019, a series of pneumonia cases caused by a SARS-CoV-2 outbreak was identified in Wuhan, Hubei, China, and rapidly spread across the world. The spectrum of SARS-CoV-2 disease (COVID 19) varies from asymptomatic or paucisymptomatic forms to clinical conditions characterized by respiratory failure that necessitate mechanical ventilation and support in an intensive care unit (ICU), multiorgan and systemic manifestations, and, in terms of sepsis, septic shock, and multiple organ dysfunction syndromes (MODS) ( 2 ). Whilst many reports have characterized the clinical, epidemiological, laboratory, and radiological features, as well as treatment and clinical outcomes of patients with COVID-19 pneumonia, information on SARS-CoV-2 reactivation remains unreported. Curative and eradicative therapy for COVID-19 is not currently available ( 3 ). We report a case of a patient with PCR-confirmed COVID-19 pneumonia who experienced reactivation after 43 days and negative PCR sampling.
【저자키워드】 COVID 19, Reactivation, naso pharingheal swab, IGM SARS-CoV2, IGG SARS-CoV2, 【초록키워드】 Treatment, SARS-CoV-2, Respiratory failure, intensive care, mechanical ventilation, Pneumonia, Sepsis, Betacoronavirus, ICU, Laboratory, Clinical outcome, Spread, China, Asymptomatic, outbreak, Wuhan, Patient, Septic shock, epidemiological, information, multiple organ dysfunction, Multiorgan, Support, SARS-CoV-2 disease, syndrome, Negative PCR, PCR-confirmed COVID-19, family Coronaviridae, clinical condition, radiological features, MODS, systemic manifestations, caused, form, characterized, Nidovirale, patients with COVID-19, pneumonia case, therapy for COVID-19, 【제목키워드】 report,